Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06803680 · ClinicalTrials.gov registry record · Phase 1

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by BeiGene.

Recruiting
Registry status
Phase 1
Development phase
90
Enrollment target
13
Study locations

NCT06803680 is a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor that is actively recruiting participants, run by BeiGene. The registered enrollment target is 90 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (53% lower). The trial reports 13 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06803680, a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, is actively recruiting participants, sponsored by BeiGene.

RECRUITING
Registry status
Phase 1
Development phase
90 participants
Enrollment target
13
Study locations

Study Summary

The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims to answer are: * What is the recommended dosing for BGB-B455? * What medical problems do participants have when taking BGB-B455? The study has two parts: * Phase 1a: dose escalation and safety expansion * Phase 1b: dose expansion

Conditions Studied

Advanced Solid Tumor Metastatic Solid Tumor

Interventions

  • DRUG Chemotherapy
  • DRUG BGB-B455

Study Locations (13)

New South Wales

  • Blacktown Cancer and Haematology Centre - Blacktown
  • Liverpool Hospital - Liverpool

Florida

  • Adventhealth - Celebration

Pennsylvania

  • Sidney Kimmel Cancer Center - Philadelphia

South Dakota

  • Avera Cancer Institute - Sioux Falls

Texas

  • Next Oncology - San Antonio

Washington

  • Fred Hutchinson Cancer Research Center - Seattle

Queensland

  • Mater Cancer Care Centre - South Brisbane

Beijing Municipality

  • Beijing Cancer Hospital - Beijing

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2025-03-18
Est. Completion 2027-10-30
Phase Phase 1

Sponsor

BeiGene

65 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06803680

The ClinicalTrials.gov registry entry for NCT06803680 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (53% lower). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Chemotherapy is the first listed.

NCT06803680 reports 13 study locations spanning 12 distinct geographic areas - top geographies include New South Wales, Florida, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06803680 about?

NCT06803680 is a clinical study titled "A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors". The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims to answer are: * What is the recommended dosing for BGB-B455? * What medical problems do participan...

What is the current status of trial NCT06803680?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2025-03-18. Estimated completion is 2027-10-30.

What conditions does trial NCT06803680 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumor.

What interventions are being tested in trial NCT06803680?

The interventions under investigation include: Chemotherapy (DRUG), BGB-B455 (DRUG).

Who is sponsoring clinical trial NCT06803680?

This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06803680 being conducted?

This trial has 13 study locations across Florida, Pennsylvania, South Dakota, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Metastatic Solid Tumor

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.